156 related articles for article (PubMed ID: 22960043)
1. Alemtuzumab induction in renal transplantation: a meta-analysis and systemic review.
Zhang X; Huang H; Han S; Fu S; Wang L
Transpl Immunol; 2012 Oct; 27(2-3):63-8. PubMed ID: 22960043
[TBL] [Abstract][Full Text] [Related]
2. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
3. Belatacept for kidney transplant recipients.
Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
[TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients: A systematic review and meta-analysis of randomized controlled trials.
Zheng J; Song W
Medicine (Baltimore); 2017 Jul; 96(28):e7151. PubMed ID: 28700465
[TBL] [Abstract][Full Text] [Related]
5. Antibody induction therapy for lung transplant recipients.
Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis.
Morgan RD; O'Callaghan JM; Knight SR; Morris PJ
Transplantation; 2012 Jun; 93(12):1179-88. PubMed ID: 22660659
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab induction in renal transplantation.
Hanaway MJ; Woodle ES; Mulgaonkar S; Peddi VR; Kaufman DB; First MR; Croy R; Holman J;
N Engl J Med; 2011 May; 364(20):1909-19. PubMed ID: 21591943
[TBL] [Abstract][Full Text] [Related]
8. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal.
Saull HE; Enderby CY; Gonwa TA; Wadei HM
Clin Transplant; 2015 Jul; 29(7):573-80. PubMed ID: 25711849
[TBL] [Abstract][Full Text] [Related]
9. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results.
Kaufman DB; Leventhal JR; Gallon LG; Parker MA
Am J Transplant; 2006 Feb; 6(2):331-9. PubMed ID: 16426317
[TBL] [Abstract][Full Text] [Related]
11. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients.
Penninga L; Wettergren A; Wilson CH; Chan AW; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD010253. PubMed ID: 24901467
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
[TBL] [Abstract][Full Text] [Related]
13. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.
Webster AC; Wu S; Tallapragada K; Park MY; Chapman JR; Carr SJ
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD004756. PubMed ID: 28731207
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis.
Hao WJ; Zong HT; Cui YS; Zhang Y
Transplant Proc; 2012 Dec; 44(10):2955-60. PubMed ID: 23195005
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
16. Induction therapy in renal transplant recipients: how convincing is the current evidence?
Wagner SJ; Brennan DC
Drugs; 2012 Mar; 72(5):671-83. PubMed ID: 22439670
[TBL] [Abstract][Full Text] [Related]
17. Depleting antibody induction in simultaneous pancreas-kidney transplantation: a prospective single-center comparison of alemtuzumab versus rabbit anti-thymocyte globulin.
Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Doares W; Kaczmorski S; Farney AC
Expert Opin Biol Ther; 2014 Dec; 14(12):1723-30. PubMed ID: 25156622
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of rATg/Daclizumab vs. rATg/Alemtuzumab as dual induction therapy in renal transplantation: Results at 8years of follow-up.
Ciancio G; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Ruiz P; Vianna R; Burke GW
Transpl Immunol; 2017 Feb; 40():42-50. PubMed ID: 27888093
[TBL] [Abstract][Full Text] [Related]
19. Delayed allograft inflammation following alemtuzumab induction for kidney transplantation.
Heilman RL; Khamash HA; Smith ML; Chakkera HA; Moss AA; Reddy KS
Clin Transplant; 2013; 27(5):772-80. PubMed ID: 23924146
[TBL] [Abstract][Full Text] [Related]
20. Acute Cellular Rejection and Infection Rates in Alemtuzumab vs Traditional Induction Therapy Agents for Lung and Heart Transplantation: A Systematic Review and Meta-analysis.
Li KHC; Ho JCS; Recaldin B; Gong M; Ho J; Li G; Liu T; Wu WKK; Wong MCS; Xia Y; Dong M; Tse G;
Transplant Proc; 2018 Dec; 50(10):3723-3731. PubMed ID: 30577263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]